SCHEMBL435247

SCHEMBL435247

CC(=O)OC1c2ccc(O)cc2OC1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRB2 P47870 1/20 0.39
ESR1 P03372 3/20 0.36
ESR2 Q92731 2/20 0.36
CYP3A4 P08684 2/20 0.36
HSD17B10 Q99714 2/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP2C9 P11712 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
ALOX12 P18054 1/20 0.35
CASP1 P29466 1/20 0.35
BRCA1 P38398 1/20 0.35
STAT6 P42226 1/20 0.35
CASP7 P55210 1/20 0.35
HBB P68871 1/20 0.35
HIF1A Q16665 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL530687 1.00 POLB (0.39) POLBGABRA1GABRB2ESR1ESR2
SCHEMBL15211580 1.00 POLB (0.39) POLBGABRA1GABRB2ESR1ESR2
SCHEMBL15211128 0.89 POLB (0.40) POLBGABRA1GABRB2ESR1ESR2
SCHEMBL1707736 0.84 POLB (0.38) POLBESR1HSD17B10ALDH1A1MEN1
SCHEMBL15211497 0.80 SLC26A4 (0.39) POLBESR1ESR2MEN1KMT2A
SCHEMBL15211233 0.77 POLB (0.34) POLBGABRA1GABRB2MEN1KMT2A
SCHEMBL15211525 0.77 POLB (0.34) POLBGABRA1GABRB2MEN1KMT2A
SCHEMBL1707740 0.75 HSD11B1 (0.41) POLBGABRA1GABRB2AKR1C3CA2
SCHEMBL9749477 0.75 ESR1 (0.41) ESR1ESR2CYP3A4HSD17B10ALDH1A1
SCHEMBL1708186 0.72 MAPT (0.42) POLBALDH1A1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7732626-B2 Fused cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-08 US disclosed
US-20100004312-A1 FUSED CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004312-A1 FUSED CYCLIC COMPOUNDS GPR119, GLP1R, GPR65 POLB 4760/4885GABRA1 534/4885GABRB2 616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.